NewEdge Wealth LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 57.2% during the 1st quarter, Holdings Channel.com reports. The firm owned 585 shares of the biopharmaceutical company’s stock after selling 781 shares during the quarter. NewEdge Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $452,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $1,012,296,000. Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Nuveen LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. Wellington Management Group LLP grew its stake in shares of Regeneron Pharmaceuticals by 8,620.0% during the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock valued at $512,881,000 after acquiring an additional 656,845 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 528.7% in the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ REGN opened at $695.18 on Wednesday. The company has a market cap of $73.49 billion, a P/E ratio of 16.94, a P/E/G ratio of 1.48 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm’s fifty day moving average is $637.83 and its two-hundred day moving average is $712.50.
Insider Activity
In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Analysts expect Regeneron’s second-quarter performance to be supported by continued demand for Dupixent, Eylea HD and Libtayo. Investors will also watch for updates on share repurchases, earnings guidance and the broader development pipeline. Will REGN’s Q2 Earnings Get a Boost From Dupixent and Eylea HD?
- Neutral Sentiment: Multiple law firms announced or promoted securities class actions against Regeneron and certain executives. The cases generally cover investors who purchased shares from August 1, 2025, through May 15, 2026, with September 14, 2026, cited as the lead-plaintiff deadline. The notices primarily repeat earlier allegations and are not new operating developments. Faruqi & Faruqi Equity Action Notice
- Negative Sentiment: The legal actions stem from disclosures about Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. Reports allege that investors were not fully informed as the trial moved from delayed event accruals to a protocol amendment and ultimately failed to meet its primary endpoint. The trial failure reportedly contributed to an approximately 9%–10% share-price decline and erased about $11 billion in market value, raising concerns about pipeline execution and potential litigation costs. Hagens Berman Regeneron Trial Alert
Analyst Ratings Changes
A number of equities research analysts have commented on the stock. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. Finally, TD Cowen raised their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $787.88.
Read Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
